Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10O5 |
Molecular Weight | 270.2369 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1O)C2=C(O)C(=O)C3=CC=CC=C3O2
InChI
InChIKey=KPGMHZQXQVDYNT-UHFFFAOYSA-N
InChI=1S/C15H10O5/c16-10-6-5-8(7-11(10)17)15-14(19)13(18)9-3-1-2-4-12(9)20-15/h1-7,16-17,19H
3′,4′-Dihydroxyflavonol (diOHF) is an antioxidant compound capable of preserving Nitric Oxide activity in the presence of reactive oxygen species, and suppressing NADPH oxidase-dependent superoxide accumulation. It has generated interest as a potential therapeutic compound, and preliminary investigations have been conducted ina number animal and in vitro models for ischemic conditions and diabetes.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27017510
Curator's Comment: the referenced study was conducted on rats
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: A5D7T0 Gene ID: 614606.0 Gene Symbol: CAMK2N2 Target Organism: Bos taurus (Bovine) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24032640 |
|||
Target ID: GO:0016175 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17916758 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro flavon-3-ol oxidation mediated by a B ring hydroxylation pattern. | 2004 Jun |
|
Vascular and anti-oxidant actions of flavonols and flavones. | 2004 Nov |
|
Vasorelaxant and antioxidant activity of flavonols and flavones: structure-activity relationships. | 2005 Sep |
|
Using behaviour to predict stroke severity in conscious rats: post-stroke treatment with 3', 4'-dihydroxyflavonol improves recovery. | 2008 Apr 14 |
|
Modulation of nicotinamide adenine dinucleotide phosphate oxidase expression and function by 3',4'-dihydroxyflavonol in phagocytic and vascular cells. | 2008 Jan |
|
Discovery of water-soluble antioxidant flavonols without vasorelaxant activity. | 2008 Oct |
|
Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein. | 2008 Oct 31 |
|
3',4'-Dihydroxyflavonol improves post-ischaemic coronary endothelial function following 7days reperfusion in sheep. | 2009 Dec 10 |
|
3',4'-Dihydroxyflavonol prevents diabetes-induced endothelial dysfunction in rat aorta. | 2009 Jul 3 |
|
Effects of 3',4'-dihydroxyflavonol on vascular contractions of rat aortic rings. | 2010 Aug |
|
Effects of resveratrol and flavonols on cardiovascular function: Physiological mechanisms. | 2010 Sep-Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21673968
Curator's Comment: the referenced study was conducted on rats
Six week old homozygous Ren-2 rats received DiOHF (1 mg/kg/day) by oral gavage for six weeks. Cardiac function was assessed via echocardiography and left ventricular cardiac catheterization before the animals were sacrificed and hearts removed for histological and molecular analyses. Treatment with DiOHF prevented the development of diastolic dysfunction and was associated with reduced oxidative stress and interstitial fibrosis.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17916758
HL-60 human myelocytic cells were cultured in RPMI 1640 containing 10% FCS. Neutrophil differentiation of HL-60 cells was induced by incubation with 1.5% DMSO for 3 to 4 days. Differentiated HL-60 cells were resuspended in Hanks' balanced salt solution containing 200 μM cytochrome c and loaded into a 96-well assay plate (∼2 × 106 cells in 100-μl volume per well). PMA 100 ng/ml was used to induce NADPH oxidase activation in HL-60 cells resulting in a burst of superoxide release as determined by SOD-inhibitable cytochrome c reduction over a period of up to 1 h. Cotreatment with DiOHF (0, 10, 30, or 100 micro-M) inhibited the PMA-induced superoxide accumulation in a concentration-dependent manner.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6068-78-6
Created by
admin on Fri Dec 15 18:47:58 GMT 2023 , Edited by admin on Fri Dec 15 18:47:58 GMT 2023
|
PRIMARY | |||
|
R1I1R1C88V
Created by
admin on Fri Dec 15 18:47:58 GMT 2023 , Edited by admin on Fri Dec 15 18:47:58 GMT 2023
|
PRIMARY | |||
|
145826
Created by
admin on Fri Dec 15 18:47:58 GMT 2023 , Edited by admin on Fri Dec 15 18:47:58 GMT 2023
|
PRIMARY | |||
|
DTXSID40209494
Created by
admin on Fri Dec 15 18:47:58 GMT 2023 , Edited by admin on Fri Dec 15 18:47:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY